Document Type : Original Article


1 Non-communicable Diseases Research Center, Department of Epidemiology, School of Health, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Community Medicine, School of Medicine, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

3 Seyed-al-Shohada Hospital, Jahrom University of Medical Sciences, Jahrom, Iran

4 Health Human Resources Research Center, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran

5 Department of Infectious Diseases, School of Medicine, Fasa University of Medical Science, Fasa, Iran



Background: The effectiveness of COVID-19 vaccination determines the resource allocation for saving lives in this pandemic. Certainly, the efficacy of all vaccines has been studied in laboratory situations. However, the present study aims to estimate the effectiveness of vaccination in real conditions of Iranian populations by controlling the effect of demographic factors and the history of chronic diseases.
Methods: This historical cohort study used information on 1988 hospitalized COVID-19 patients with less than 93% blood oxygen levels. Cox regression, Survival Tree, and Forests were applied to estimate the effect of immunity from vaccination on survival, while the effect of demographic characteristics and history of chronic diseases was controlled.
Results: The analysis showed that 10% of the patients were immunized, while the Sinopharm vaccine and the rest by Sputnik induced 86% of the immunity. Although there was no difference in the effectiveness of the vaccines, it was found that the immunity from each vaccine increased survival. Patient age was identified as the most influential factor in survival. Other contributing factors include the history of opium/smoking, cancer, the history of chronic lung disease, kidney disease, high blood pressure, and cardiovascular problems.
Conclusion: Although age is the most influential factor in patient survival, immunity can control the risk of COVID-19. Therefore, it is recommended to prioritize the old and patients with any of the above underlying problems for vaccination and timely treatment.


  1. Liu W, Yang C, Liao YG, Wan F, Lin L, Huang X, Zhang BH, et al. Risk factors for COVID-19 progression and mortality in hospitalized patients without pre-existing comorbidities. J Infect Public Health. 2022 Jan;15(1):13-20. doi: 10.1016/j.jiph.2021.11.012. Epub 2021 Nov 18. PMID: 34861603; PMCID: PMC8598256.
  2. Moftakhar L, Seif M, Safe MS. Exponentially Increasing Trend of Infected Patients with COVID-19 in Iran: A Comparison of Neural Network and ARIMA Forecasting Models. Iran J Public Health. 2020 Oct;49(Suppl 1):92-100. doi: 10.18502/ijph.v49iS1.3675. PMID: 34268211; PMCID: PMC8266002.
  3. [Available from:
  4. Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, Chen YM, Lai YC, Kuo LC, Chen SD, Chang KJ, Liu CH, Chang SC, Wang FD, Yang YP. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021 Jan 1;84(1):3-8. doi: 10.1097/JCMA.0000000000000463. PMID: 33230062.
  5. Niroomand N, Bayati M, Seif M, Delavari S, Delavari S. Self-medication Pattern and Prevalence Among Iranian Medical Sciences Students. Curr Drug Saf. 2020;15(1):45-52. Doi: 10.2174/1574886314666191022095058. PMID: 31642791.
  6. Ren X, Li Y, Yang X, Li Z, Cui J, Zhu A, Zhao H, Yu J, Nie T, Ren M, Dong S, Cheng Y, Chen Q, Chang Z, Sun J, Wang L, Feng L, Gao GF, Feng Z, Li Z. Evidence for pre-symptomatic transmission of coronavirus disease 2019 (COVID-19) in China. Influenza Other Respir Viruses. 2021 Jan;15(1):19-26. doi: 10.1111/irv.12787. Epub 2020 Aug 7. PMID: 32767657; PMCID: PMC7436222.
  7. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID-19). 2023 Jan 9. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan–. PMID: 32150360.
  8. Ghaebi M, Tahmasebi S, Jozghorbani M, Sadeghi A, Thangavelu L, Zekiy AO, Esmaeilzadeh A. Risk factors for adverse outcomes of COVID-19 patients: Possible basis for diverse responses to the novel coronavirus SARS-CoV-2. Life Sci. 2021 Jul 15;277:119503. doi: 10.1016/j.lfs.2021.119503. Epub 2021 Apr 15. PMID: 33865882; PMCID: PMC8046708.
  9. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brüggen MC, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021 Feb;76(2):428-455. doi: 10.1111/all.14657. Epub 2020 Dec 4. PMID: 33185910.
  10. Luo J, Zhu X, Jian J, Chen X, Yin K. Cardiovascular disease in patients with COVID-19: evidence from cardiovascular pathology to treatment. Acta Biochim Biophys Sin (Shanghai). 2021 Mar 2;53(3):273-282. doi: 10.1093/abbs/gmaa176. PMID: 33428706; PMCID: PMC7929476.
  11. Muñoz-Rodríguez JR, Gómez-Romero FJ, Pérez-Ortiz JM, López-Juárez P, Santiago JL, Serrano-Oviedo L, et al; COVID-19 SESCAM Network. Characteristics and Risk Factors Associated With Mortality in a Multicenter Spanish Cohort of Patients With COVID-19 Pneumonia. Arch Bronconeumol. 2021 Apr;57:34-41. doi: 10.1016/j.arbres.2021.02.021. Epub 2021 Mar 9. PMID: 34629641; PMCID: PMC7939995.
  12. Erdal GS, Polat O, Erdem GU, Korkusuz R, Hindilerden F, Yilmaz M, et al. The mortality rate of COVID-19 was high in cancer patients: a retrospective single-center study. Int J Clin Oncol. 2021 May;26(5):826-834. doi: 10.1007/s10147-021-01863-6. Epub 2021 Jan 24. PMID: 33486624; PMCID: PMC7826293.
  13. Bowles KH, McDonald M, Barrón Y, Kennedy E, O'Connor M, Mikkelsen M. Surviving COVID-19 After Hospital Discharge: Symptom, Functional, and Adverse Outcomes of Home Health Recipients. Ann Intern Med. 2021 Mar;174(3):316-325. doi: 10.7326/M20-5206. Epub 2020 Nov 24. PMID: 33226861; PMCID: PMC7707212.
  14. Ambale-Venkatesh B, Quinaglia T, Shabani M, Sesso J, Kapoor K, Matheson MB, et al. Prediction of Mortality in hospitalized COVID-19 patients in a statewide health network. medRxiv [Preprint]. 2021 Feb 19:2021.02.17.21251758. doi: 10.1101/2021.02.17.21251758. PMID: 33619510; PMCID: PMC7899480.
  15. Ortiz RIH, Barrera JCB, Barrera KMB, editors. Analysis model of the most important factors in Covid-19 through data mining, descriptive statistics and random forest. 2020 IEEE International Autumn Meeting on Power, Electronics and Computing (ROPEC); 2020: IEEE. doi: 10.1109/ROPEC50909.2020.9258765.
  16. Osi AA, Abdu M, Muhammad U, Ibrahim A, Isma’il LA, Suleiman AA, et al. A Classification Approach for Predicting COVID-19 Patient’s Survival Outcome with Machine Learning Techniques. medRxiv. January 2022Science Forum (Journal of Pure and Applied Sciences) 22(1):1, doi: 10.5455/sf.aaosi2.
  17. Alsulami M, Abu-Zinadah H, Ibrahim AH. Machine Learning Model and Statistical Methods for COVID-19 Evolution Prediction. Wireless Communications and Mobile Computing. 2021;2021. doi: 10.1155/2021/4840488.
  18. Escobar-Agreda S, Silva-Valencia J, Rojas-Mezarina L, Vargas-Herrera J. Survival of health workers infected by SARS-CoV-2 in the context of vaccination against COVID-19 in Peru. medRxiv. 2021.doi: 10.1101/2021.08.03.21260614.
  19. Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284-1290. doi: 10.15585/mmwr.mm7037e1. PMID: 34529637; PMCID: PMC8445374.
  20. Štefan M, Dlouhý P, Bezdíčková L. [Vaccination against COVID-19]. Klin Mikrobiol Infekc Lek. 2021 Jun;27(2):49-60. Czech. PMID: 34648642.
  21. Muthukrishnan J, Vardhan V, Mangalesh S, Koley M, Shankar S, Yadav AK, et al. Vaccination status and COVID-19 related mortality: A hospital based cross sectional study. Med J Armed Forces India. 2021 Jul;77(Suppl 2):S278-S282. doi: 10.1016/j.mjafi.2021.06.034. Epub 2021 Jul 26. PMID: 34334894; PMCID: PMC8313045.
  22. Yang Q, Li J, Zhang Z, Wu X, Liao T, Yu S, et al. Clinical characteristics and a decision tree model to predict death outcome in severe COVID-19 patients. BMC Infect Dis. 2021 Aug 9;21(1):783. doi: 10.1186/s12879-021-06478-w. PMID: 34372767; PMCID: PMC8351764.
  23. Dietz K, Gail M, Krickeberg K, Samet J, Tsiatis A. Statistics for biology and health. Survival Analysis, Edition Springer. 2002;7.
  24. An C, Lim H, Kim DW, Chang JH, Choi YJ, Kim SW. Machine learning prediction for mortality of patients diagnosed with COVID-19: a nationwide Korean cohort study. Sci Rep. 2020 Oct 30;10(1):18716. doi: 10.1038/s41598-020-75767-2. PMID: 33127965; PMCID: PMC7599238.
  25. Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging (Albany NY). 2020 May 29;12(10):9959-9981. doi: 10.18632/aging.103344. Epub 2020 May 29. PMID: 32470948; PMCID: PMC7288963.
  26. Liu Y, Yan LM, Wan L, Xiang TX, Le A, Liu JM, Peiris M, Poon LLM, Zhang W. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020 Jun;20(6):656-657. doi: 10.1016/S1473-3099(20)30232-2. Epub 2020 Mar 19. PMID: 32199493; PMCID: PMC7158902.
  27. Blagosklonny MV. From causes of aging to death from COVID-19. Aging (Albany NY). 2020 Jun 12;12(11):10004-10021. doi: 10.18632/aging.103493. Epub 2020 Jun 12. PMID: 32534452; PMCID: PMC7346074.
  28. AlQahtani M, Bhattacharyya S, Alawadi A, Mahmeed HA, Sayed JA, Justman J, et al. Morbidity and mortality from COVID-19 post-vaccination breakthrough infections in association with vaccines and the emergence of variants in Bahrain. 2021. doi: 21203/
  29. Hodgson SH, Mansatta K, Mallett G, Harris V, Emary KRW, Pollard AJ. What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. Lancet Infect Dis. 2021 Feb;21(2):e26-e35. doi: 10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27. PMID: 33125914; PMCID: PMC7837315.
  30. Evidence Assessment: Sinopharm/BBIBP COVID-19 Vaccine. World Health Organization; 2021.
  31. Shapiro J, Dean NE, Madewell ZJ, Yang Y, Halloran ME, Longini IM. Efficacy estimates for various COVID-19 vaccines: what we know from the literature and reports. medRxiv. 2021. doi: 10.1101/2021.05.20.21257461.
  32. Tenforde MW, Self WH, Adams K, Gaglani M, Ginde AA, McNeal, et al. Influenza and Other Viruses in the Acutely Ill (IVY) Network. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021 Nov 23;326(20):2043-2054. doi: 10.1001/jama.2021.19499. PMID: 34734975; PMCID: PMC8569602.
  33. Riahi T, Sadeghzadeh-Bazargan A, Shokri S, Ahmadvand D, Hassanlouei B, Baghestani A, Khazaeian A, Seifi Gharabaghloo F, Hassanzadeh M, Goodarzi A. The effect of opium on severity of COVID-19 infection:An original study from Iran. Med J Islam Repub Iran. 2021 Sep 8;35:115. doi: 10.47176/mjiri.35.115. PMID: 34956961; PMCID: PMC8683804.
  34. Dolati-Somarin A, Abd-Nikfarjam B. The Reasons for Higher Mortality Rate in Opium Addicted Patients with COVID-19: A Narrative Review. Iran J Public Health. 2021 Mar;50(3):470-479. doi: 10.18502/ijph.v50i3.5587. PMID: 34178794; PMCID: PMC8214617.
  35. Curigliano G. Cancer Patients and Risk of Mortality for COVID-19. Cancer Cell. 2020 Aug 10;38(2):161-163. doi: 10.1016/j.ccell.2020.07.006. Epub 2020 Jul 25. PMID: 32710820; PMCID: PMC7381394.
  36. Addeo A, Friedlaender A. Cancer and COVID-19: Unmasking their ties. Cancer Treat Rev. 2020 Aug;88:102041. doi: 10.1016/j.ctrv.2020.102041. Epub 2020 Jun 3. PMID: 32516704; PMCID: PMC7831797.
  37. Wu ZH, Tang Y, Cheng Q. Diabetes increases the mortality of patients with COVID-19: a meta-analysis. Acta Diabetol. 2021 Feb;58(2):139-144. doi: 10.1007/s00592-020-01546-0. Epub 2020 Jun 24. PMID: 32583078; PMCID: PMC7311595.
  38. Li J, Huang DQ, Zou B, Yang H, Hui WZ, Rui F, et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J Med Virol. 2021 Mar;93(3):1449-1458. doi: 10.1002/jmv.26424. Epub 2020 Aug 25. PMID: 32790106; PMCID: PMC7436673.
  39. Abate BB, Kassie AM, Kassaw MW, Aragie TG, Masresha SA. Sex difference in coronavirus disease (COVID-19): a systematic review and meta-analysis. BMJ Open. 2020 Oct 6;10(10):e040129. doi: 10.1136/bmjopen-2020-040129. PMID: 33028563; PMCID: PMC7539579.
  40. Cai H. Sex difference and smoking predisposition in patients with COVID-19. Lancet Respir Med. 2020 Apr;8(4):e20. doi: 10.1016/S2213-2600(20)30117-X. Epub 2020 Mar 11. Erratum in: Lancet Respir Med. 2020 Apr;8(4):e26. PMID: 32171067; PMCID: PMC7103991.
  41. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020 May 25;11(1):29. doi: 10.1186/s13293-020-00304-9. PMID: 32450906; PMCID: PMC7247289.
  42. Abdi A, Jalilian M, Sarbarzeh PA, Vlaisavljevic Z. Diabetes and COVID-19: A systematic review on the current evidences. Diabetes Res Clin Pract. 2020 Aug;166:108347. doi: 10.1016/j.diabres.2020.108347. Epub 2020 Jul 22. PMID: 32711003; PMCID: PMC7375314.
  43. Peña JE, Rascón-Pacheco RA, Ascencio-Montiel IJ, González-Figueroa E, Fernández-Gárate JE, Medina-Gómez OS, Borja-Bustamante P, et al. Borja-Aburto VH. Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico. Arch Med Res. 2021 May;52(4):443-449. doi: 10.1016/j.arcmed.2020.12.002. Epub 2020 Dec 16. PMID: 33380361; PMCID: PMC7832055.
  44. Ferroni E, Giorgi Rossi P, Spila Alegiani S, Trifirò G, Pitter G, Leoni O, et al. Survival of Hospitalized COVID-19 Patients in Northern Italy: A Population-Based Cohort Study by the ITA-COVID-19 Network. Clin Epidemiol. 2020 Dec 8;12:1337-1346. doi: 10.2147/CLEP.S271763. PMID: 33335428; PMCID: PMC7737545.
  45. Marimuthu Y, Kunnavil R, Anil NS, Nagaraja SB, Satyanarayana N, Kumar J, et al. Clinical profile and risk factors for mortality among COVID-19 inpatients at a tertiary care centre in Bengaluru, India. Monaldi Arch Chest Dis. 2021 May 17;91(3). doi: 10.4081/monaldi.2021.1724. PMID: 34006039.
  46. Boëlle PY, Delory T, Maynadier X, Janssen C, Piarroux R, Pichenot M, et al. Trajectories of Hospitalization in COVID-19 Patients: An Observational Study in France. J Clin Med. 2020 Sep 29;9(10):3148. doi: 10.3390/jcm9103148. PMID: 33003375; PMCID: PMC7600846.
  47. Ashinyo ME, Duti V, Dubik SD, Amegah KE, Kutsoati S, Oduro-Mensah E, et al. Clinical characteristics, treatment regimen and duration of hospitalization among COVID-19 patients in Ghana: a retrospective cohort study. Pan Afr Med J. 2020 Sep 15;37(Suppl 1):9. doi: 10.11604/pamj.supp.2020.37.9.25718. PMID: 33294110; PMCID: PMC7704352.
  48. Thai PQ, Toan DTT, Son DT, Van HTH, Minh LN, Hung LX, te al. Factors associated with the duration of hospitalisation among COVID-19 patients in Vietnam: A survival analysis. Epidemiol Infect. 2020 Jun 10;148:e114. doi: 10.1017/S0950268820001259. PMID: 32517822; PMCID: PMC7306545.
  49. Shao F, Xu S, Ma X, Xu Z, Lyu J, Ng M, te al. In-hospital cardiac arrest outcomes among patients with COVID-19 pneumonia in Wuhan, China. Resuscitation. 2020 Jun;151:18-23. doi: 10.1016/j.resuscitation.2020.04.005. Epub 2020 Apr 10. PMID: 32283117; PMCID: PMC7151543.
  50. Seif M, Sharafi M, Ghaem H, Kasraei F. Factors associated with survival of Iranian patients with COVID-19: comparison of Cox regression and mixture cure model. Trop Dis Travel Med Vaccines. 2022 Mar 1;8(1):4. doi: 10.1186/s40794-022-00162-w. PMID: 35227332; PMCID: PMC8885138.